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Abstract
Asthma affects nearly 300 million people worldwide, with 250,000 associated deaths
annually. An estimated 5%-10% of patients have severe asthma, while only 1%-2% presented
with treatment-resistant or refractory asthma. Currently, the endotype of asthma is divided
into T-helper type 2 (Th2) high and Th2-low inflammation endotypes. The Th2-high endotype
is characterized by eosinophilic asthma, while the Th2-low endotype is associated with
neutrophilia and a pauci-granulocytic profile. The Th2-low endotype carries a high resistance
to corticosteroid and bronchodilator therapy, and these patients typically have a severe and
acute-onset of symptoms. We present a 57-year-old nonsmoking female with recurrent
intensive care unit (ICU) admissions for severe acute asthma exacerbations, resistant to
bronchodilator and steroid treatment, requiring mechanical ventilation. Currently, the
guidelines for treating neutrophil-predominant Th2-low inflammation asthma have not been
established. This creates a management dilemma when encountered with such a patient in
clinical practice. We aim to propose targeted treatment options for these severe and potentially
fatal asthma patients, with reference to current literature.
Categories: Internal Medicine, Preventive Medicine, Pulmonology
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Introduction
Asthma is an inflammatory process which reversibly obstructs small airways, leading to
bronchial hyper-responsiveness. Asthma affects 300 million people worldwide with an annual
death rate of 250,000 per year. Most of the patients with asthma are symptomatically controlled
with currently available treatment options. However, 1%-2% of patients are treatment-resistant
with severe refractory asthma. After an acute exacerbation, an estimated 30% of patients get
admitted to the intensive care unit (ICU) with a mortality rate as high as 8%. Approximately 4%
of patients require mechanical ventilation due to severe asthma. Severe asthma patients who
get admitted to the ICU have a higher risk of death [1-4]. We present a 57-year-old female with
multiple ICU admissions due to severe treatment-resistant asthma exacerbations.
Case Presentation
A 57-year-old nonsmoking Caucasian female was brought to the hospital by her husband due to
sudden shortness of breath. Upon admission, the patient received nebulizer treatment and
intravenous steroids, but her condition continued to deteriorate and required an urgent
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transfer to the ICU, in which she was placed on mechanical ventilation. The patient presented a
few times similarly in the past couple of months, requiring mechanical ventilation every visit.
According to the patient's husband, the patient had no sick contact, recent travel, or a
productive cough before admission. He also stated that she did not complain of chest pain or
shortness of breath upon exertion.
Upon physical exam, she was on a ventilator, resting comfortably. Her vitals were as follows: a
blood pressure of 113/60 mmHg, a pulse of 108 beats per minute (bpm), a temperature of
98.0°F, a respiratory rate of 20 breaths per minute (bpm), and a pulse oximeter of 99% on 60%
Fi02. The patient had expiratory wheezes heard bilaterally. The patient’s heart had regular rate
and rhythm, with no murmurs, gallops, or rubs heard on auscultation. There was no jugular
venous distension or peripheral edema noted in all extremities.
After admission, a computed tomography angiography (CTA) was done to rule out a possible
pulmonary embolism. Results were negative, along with cardiac workup. The immunoglobulin
epsilon (IgE) levels were within reasonable limits. The hematology results showed a
significantly high white blood cell (WBC) count with neutrophil predominance, as shown in
Table 1.
The patient was sent to the university hospital and seen by an immunologist and allergist. She
was given Daliresp (roflumilast) along with azithromycin. Upon medication, symptoms
significantly improved with no further acute asthma episodes requiring outpatient and
hospitalized visits. 
Collected Result Units Reference range
White blood cell 14.1 X 103 4.8-10.8
Hemoglobin 10.3 X106 12.0-16.0
Hematocrit 32.2 % 37.0-47.0
Red blood cell 3.64 X106 4.20-5.40
Platelet 257 X103 130-400
Neutrophils count 10.1 X103 1.5-7.1
Eosinophil count 0.0 X103 0.0-8.0
Basophil count 0.0 X103 0.0-0.1
Lymphocyte count 2.4 X103 0.7-4.3
TABLE 1: Hematology results.
Discussion
Once the diagnosis of acute asthma exacerbation is established and the comorbidities and
confounders are excluded, the European respiratory society (EUS) and American thoracic society
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(ATS) define severe asthma as patients treated with high dose inhaled corticosteroids and a
bronchodilator or systemic corticosteroid, but their asthma remains uncontrolled despite
treatment [5]. Inflammation has a critical role in the pathophysiology of asthma. Immune cells
and other immune mediators cause bronchiolar constriction and decrease the diameter of
airflow, causing expiratory wheezing, cough, and shortness of breath. Currently, the endotype
of asthma is divided into Th2 high and Th2 low inflammation. The standard approach to
phenotyping of asthma is based on clinical presentation, associated triggers in a demographic
area, and pathological factors. The phenotypical differentiation is not only significant to
recognize the disease, but it also helps to follow the response to the medication. The new
techniques include biological and specific organ sampling along with the use of inflammatory
markers help to differentiate asthma phenotypes. For example, based on the phenotypical
presentation, asthma is divided into eosinophilic and noneosinophilic asthma. Eosinophilic
asthma has a slow, gradual onset with a slow but effective response to treatment. Neutrophilic
asthma occurs rapidly with a quick response to treatment, but patients tend to relapse
quickly [4-9].
Th2-high endotype upregulates the expression of T helper type 2 cluster designation (CD) 4+
lymphocytes, leading to the stimulation of cytokines like interleukin (IL) 4, IL5 and IL-13,
causing an increase in eosinophil counts in the sputum and airway. The Th2-high endotype
eosinophilic asthma is often responsive to steroid therapy. The majority of treatment for
asthma is aimed at targeting type 2 inflammation and is directed toward the Th2-High
endotype. Anti-IgE therapy was the first effective monoclonal antibody against allergic asthma
and given to a patient whose serum IgE level ≥ 30 international unit/milliliters (IU/ml).
Presently, two anti-IL5 agents such as mepolizumab and reslizumab have been approved for use
in severe eosinophilic asthma. IL5 receptor inhibitors, reslizumab have shown to decrease
exacerbation in eosinophilic phenotype asthma. Also, anti-IL-4 receptor alpha therapy like
dupiumab has shown to reduce severe asthma exacerbations and has a more significant benefit
in patients with higher eosinophil levels [10]. Other medicines that are currently under
experiments include anti-thymic stromal lymphopoietin such as tezeplumab, which has shown
improvements of severe asthma symptoms in phase IIb clinical trial. The anti-IL-13 antibody
tralokinumab has shown inconsistent results in phase III trials, indicating no benefit in
treating severe asthma symptoms [11-12].
The pathogenesis of severe acute asthma has not been well established, but bronchial biopsies
showed the presence of neutrophilia. The prominent neutrophil counts were also seen in
patients with fatal sudden-onset asthma, and they might play an important role in
exacerbating asthma. Corticosteroid-resistant asthma mainly is present in adults and is
associated with comorbid conditions such as obesity, smoking, low vitamin D levels, and are
noneosinophilic (low-Th2 inflammation). The Th2-low endotype does not have any specific
biomarker available and is often diagnosed by the exclusion of Th2-high biomarkers. The Th2-
low endotype manifests with increased neutrophils and pauci-granulocytic profile. Sur et al.
concluded that fast-onset asthma has excess neutrophils relative to eosinophils in the airway
submucosa [6] The recruitment of neutrophils involves multiple pathways such as tumor
necrosis factor, IL-1, IL-6, IL-8, IL-23, and IL-17 [13].
Currently, there is no specific treatment established for Th2-low asthma. Inhaled steroids can
block epithelial IL-8 secretion. However, in a patient with severe asthma, IL-8 concentrations
remain significantly high despite a higher dosage. The long-term use of steroids inhibits
neutrophil apoptosis which may lead to increasing the neutrophilic count. This may be the
reason behind why neutrophil-predominant asthma is resistant to corticosteroids and
conventional therapy. The release of IL-8 from neutrophils in the airway leads to an increase in
recruitment and activation of neutrophils in the submucosa via C-X-C chemokine receptor 2
(CXCR2). A conclusion of a small double-blinded study done by Todd et al. stated that dual C-X-
C chemokines receptors 1 (CXCR1) and CXCR2, antagonists showed a decrease in the amount
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of circulatory and airway neutrophils via inhibiting its migration [13]. A phase 2 study showed
that CXCR2 antagonist SCH527123 is safe and decreases the sputum neutrophils and improves
severe asthma symptoms. Macrolides, such as clarithromycin and azithromycin also modulate
IL-8 levels along with neutrophil accumulation and activation. It can be a long-term add-on
with conservative therapy in a patient with noneosinophilic asthma. However, clinicians should
be aware of antibiotic-resistance and its side effects [5, 14-16]. A selective blocker of
phosphodiesterase-4 such as roflumilast has shown an improvement in ovalumin-asthmatic
mice when combined with fluticasone by decreasing the eosinophils, neutrophils, and
macrophage counts in bronchoalveolar lavage fluid [17].
Meanwhile, another clinical trial using CXCR2 antagonist AZD5069 as add-on therapy has
shown no significant improvement in patients with severe asthma. The studies using anti-
tumor necrosis factor-alpha antibodies for asthma was inconclusive regarding efficacy and had
substantial side effects such as infection and malignancy [13, 16]. A randomized control trial of
patients with severe asthma treated with the human monoclonal antibody that binds to IL-17
receptor alpha (IL-17Ra) such as brodalumab did not show significant improvement in asthma
control. However, the trial was stopped due to side effect such as mental health problem such as
suicide. The other IL-17Ra such as secukinumab also did not influence sputum neutrophil
counts from baseline in healthy individuals [15, 18]. There are limited treatment options
available for Th2-low endotype asthma, and further studies are needed to understand the
underlying mechanism and find proper treatment.
Conclusions
Inhaled steroid and bronchodilator or systemic steroid therapy is inadequate for the Th2-low,
neutrophil-predominant endotype of asthma. There are currently no specific treatment
guidelines for Th2-low endotype asthma with resistance to available treatment. Recent new
medications are explicitly targeting the Th2-high endotype or eosinophilic asthma. The role of
specific inflammatory mediators that present in asthma requires an accurate disease sub-
phenotyping to optimize the management and to develop an appropriate therapy. For severe
and acute-onset asthma resistant to available treatment, understanding that they may have the
Th2 low-inflammation endotype and knowing some treatment alternatives for this type of
asthma might help prevent recurrent ICU admissions and possibly death. 
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